Lonza completes Capsugel acquisition for $5.5 billion

By Stephen Daniells

- Last updated on GMT

© iStock/Kritchanut
© iStock/Kritchanut
Switzerland’s Lonza has completed the acquisition of Capsugel S.A. from KKR after receiving all the required regulatory approvals.

The acquisition aligns with Lonza’s strategy to accelerate its growth and ability to deliver value along the healthcare continuum, said the company in a release.

“Lonza and Capsugel have a highly synergistic customer base and market approach, complementary business models and closely aligned corporate cultures with a strong commitment to ethics and compliance. All of these aspects will facilitate a seamless integration,” ​said Richard Ridinger, Lonza's CEO.

The $5.5 billion transaction price includes approximately $2 billion for refinancing of existing Capsugel debt. Capsugel’s business will continue to operate in its existing structure until the full integration has been completed, said Lonza.

Acquisition trail

Last year, Lonza acquired Benicia, CA-based InterHealth Nutraceuticals,​ a nutritional ingredient research, development, and manufacture company, for $300 million.

InterHealth’s flagship ingredient is UC-II for join-health, although the company offers more than 15 branded ingredients.

Related topics: Manufacturers, Suppliers, Financial plays

Related news

Follow us

Featured Events

View more

Products

View more

Webinars